Literature DB >> 8435807

Prognostic significance of bone metastases in patients with metastatic prostate cancer.

K Yamashita1, K Denno, T Ueda, Y Komatsubara, T Kotake, M Usami, O Maeda, S Nakano, Y Hasegawa.   

Abstract

BACKGROUND: The distribution of bone metastases on a bone scan has not been duly considered when assessing the prognosis of metastatic prostate cancer.
METHODS: The medical records of 76 patients with newly diagnosed, untreated metastatic prostate cancer were reviewed. According to the distribution of bone metastases on the initial bone scan, we divided the patients into three groups: Group I (having bone metastases exclusively within the pelvis and the lumbar spine), Group II (having bone metastases exclusively outside these bones), and Group III (having bone metastases in both areas).
RESULTS: Among the responders to androgen deprivation, those in Group I survived significantly longer than did those in Groups II or III. Because the extent of the disease and the distribution of histologic differentiation in Groups I and II were similar, the results indicate that the presence of bone metastases outside the pelvis and the lumbar spine is predictive of short survival time. This prediction was not possible when the extent of disease (EOD) grading system was used.
CONCLUSION: The distribution of bone metastases on the initial bone scan should be considered as a variable for the prognostic stratification of patients with metastatic prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435807     DOI: 10.1002/1097-0142(19930215)71:4<1297::aid-cncr2820710421>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma.

Authors:  Lujun Shen; Jun Dong; Sheng Li; Yue Wang; Annan Dong; Wanhong Shu; Ming Wu; Changchuan Pan; Yunfei Xia; Peihong Wu
Journal:  Oncologist       Date:  2015-02-06

2.  Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.

Authors:  Gustavo S P Meirelles; Heiko Schöder; Gregory C Ravizzini; Mithat Gönen; Josef J Fox; John Humm; Michael J Morris; Howard I Scher; Steven M Larson
Journal:  Clin Cancer Res       Date:  2010-10-25       Impact factor: 12.531

3.  Predictive value of the clinically and scintigraphically important bone lesions in hormone-refractory prostate cancer (HRPC).

Authors:  Athanasios Zafeirakis; Georgios S Limouris
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

4.  Accuracy of prognostic scores in decision making and predicting outcomes in metastatic spine disease.

Authors:  H Majeed; S Kumar; R Bommireddy; Z Klezl; D Calthorpe
Journal:  Ann R Coll Surg Engl       Date:  2012-01       Impact factor: 1.891

5.  Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.

Authors:  Hossein Jadvar; Bhushan Desai; Lingyun Ji; Peter S Conti; Tanya B Dorff; Susan G Groshen; Jacek K Pinski; David I Quinn
Journal:  J Nucl Med       Date:  2013-06-19       Impact factor: 10.057

6.  Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer.

Authors:  Ken-Ichi Tabata; Yuzuru Niibe; Takefumi Satoh; Hideyasu Tsumura; Masaomi Ikeda; Satoru Minamida; Tetsuo Fujita; Daisuke Ishii; Masatsugu Iwamura; Kazushige Hayakawa; Shiro Baba
Journal:  Pulm Med       Date:  2012-09-09

Review 7.  Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?

Authors:  Edith D Canby-Hagino; Gregory P Swanson; E David Crawford; Joseph W Basler; Javier Hernandez; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 2.862

Review 8.  Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.

Authors:  Onita Bhattasali; Leonard N Chen; Michael Tong; Siyuan Lei; Brian T Collins; Pranay Krishnan; Christopher Kalhorn; John H Lynch; Simeng Suy; Anatoly Dritschilo; Nancy A Dawson; Sean P Collins
Journal:  Front Oncol       Date:  2013-12-03       Impact factor: 6.244

9.  18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation.

Authors:  Constantin Lapa; Katharina Lückerath; Uwe Malzahn; Samuel Samnick; Herrmann Einsele; Andreas K Buck; Ken Herrmann; Stefan Knop
Journal:  Oncotarget       Date:  2014-09-15

10.  Analysis of regional bone scan index measurements for the survival of patients with prostate cancer.

Authors:  Jonas Kalderstam; May Sadik; Lars Edenbrandt; Mattias Ohlsson
Journal:  BMC Med Imaging       Date:  2014-07-10       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.